Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands-Reference-Cited by-同舟云学术

Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands

Published:2022-06-02 Issue:12 Volume:65 Page:8380-8400
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Liosi Maria-Elena¹,Ippolito Joseph A.¹,Henry Sean P.¹,Krimmer Stefan G.¹²,Newton Ana S.¹^ORCID,Cutrona Kara J.¹,Olivarez Rene A.¹,Mohanty Jyotidarsini²,Schlessinger Joseph²^ORCID,Jorgensen William L.¹^ORCID

Affiliation:

1. Department of Chemistry, Yale University, New Haven, Connecticut 06520-8107, United States

2. Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520-8066, United States

Funder

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00283

Reference54 articles.

1. The Janus kinases (Jaks)

2. JAKs and STATs in Immunity, Immunodeficiency, and Cancer

3. JAKS AND STATS: Biological Implications

4. Janus Kinases in Leukemia

5. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Janus Kinases and Autoimmunity: Bridging Pathways to Therapy;International Journal of Drug Discovery and Pharmacology;2024-06-05

2. Breviscapine ameliorates autophagy by activating the JAK2/STAT5/BCL2 pathway in a transient cerebral ischemia rat model;Journal of Neuropathology & Experimental Neurology;2024-05-28

3. Insight into Janus kinases specificity: From molecular architecture to cancer therapeutics;MedComm – Oncology;2024-03

4. Progress on the Pharmacological Targeting of Janus Pseudokinases;Journal of Medicinal Chemistry;2023-08-14

5. Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches;Blood Cancer Discovery;2023-07-27